The investigational monoclonal antibody clesrovimab protected against respiratory syncytial virus (RSV) disease and prevented RSV hospitalizations among healthy preterm- and term infants ...

If you continue to have this issue please contact customerservice@slackinc.com. Clesrovimab was 91% effective at preventing medically attended lower respiratory tract infections vs. placebo.

In the Phase 2b/3 trial, clesrovimab reduced RSV-associated hospitalizations (secondary endpoint) and RSV-associated lower respiratory infection hospitalizations (tertiary endpoint) by more than ...

The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the middle of next year. If approved by the 10th June action date, clesrovimab ...

Three months after revealing that its respiratory syncytial virus (RSV) preventive antibody clesrovimab had passed muster in a phase 2b/3 trial, Merck is putting numbers to the claim. Clesrovimab ...

The incidence of treatment-related side effects were comparable between the clesrovimab and placebo groups, Merck said, adding that there were no treatment or RSV-related deaths during the study.

Results from the Phase 2b/3 trial of single dose of clesrovimab in healthy preterm and full-term infants met all prespecified endpoints. Interim data showed clesrovimab had a comparable safety ...

Merck’s (NYSE:MRK) monoclonal antibody clesrovimab, designed as a prophylactic against respiratory syncytial virus (RSV), has reduced the RSV-associated lower respiratory infections by roughly ...

Merck, known as MSD outside of the United States and Canada, announced the presentation of positive results from the phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the company’s ...

(RTTNews) - Merck (MRK) announced the FDA has accepted the Biologics License Application for clesrovimab, or MK-1654, the company's investigational prophylactic long-acting monoclonal antibody ...

Please provide your email address to receive an email when new articles are posted on . Clesrovimab is a monoclonal antibody that protects against RSV subtypes A and B. The FDA set a PDUFA date ...